RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Author:
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Link
http://www.nature.com/articles/nrd3625.pdf
Reference108 articles.
1. Davidson, B. L. & McCray, P. B. Jr. Current prospects for RNA interference-based therapies. Nature Rev. Genet. 12, 329–340 (2011).
2. Goodchild, J. Therapeutic oligonucleotides. Methods Mol. Biol. 764, 1–15 (2011).
3. Crooke, S. T. Vitravene — another piece in the mosaic. Antisense Nucleic Acid Drug Dev. 8, vii–viii (1998). This is a paper on the first — and so far the only — antisense oligonucleotide drug approved for use as a treatment for cytomegalovirus-induced retinitis in patients with advanced AIDS.
4. Moshfeghi, A. A. & Puliafito, C. A. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin. Investig. Drugs 14, 671–682 (2005).
5. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806–811 (1998).
Cited by 1001 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting alternative splicing of fibronectin in human renal proximal tubule epithelial cells with antisense oligonucleotides to reduce EDA+ fibronectin production and block an autocrine loop that drives renal fibrosis;Experimental Cell Research;2024-09
2. Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress;Molecular Therapy - Nucleic Acids;2024-09
3. Current status and trends in small nucleic acid drug development: Leading the future;Acta Pharmaceutica Sinica B;2024-09
4. Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside;Cancers;2024-08-23
5. Identification of a novel alternative splicing isoform of the Hippo kinase STK3/MST2 with impaired kinase and cell growth suppressing activities;Oncogene;2024-08-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3